Gilead Sciences Offers Only Enough Free Truvada to Ensure The Disease is Never Brought Fully Under Control

Gilead may have alternative motives for offering the anti-HIV drug for free

Truvada Bone Lawsuit News

Tuesday, August 27, 2019 - Critics of Gilead Sciences Truvada free giveaway are incensed and think that the only group of people that the program will benefit may be Gilead Sciences itself. Gilead Sciences has agreed to work with the US government and the Trump administration to offer 200,000 bottles of the anti-HIV drug Truvada for free to non-insured individuals starting in 2020 and every year for the next 10-15 years. On the surface, it seems like the company is being generous and "sharing their windfall" to help the thousands of individuals who could not ordinarily afford Truvada's prohibitive $20,000 per year price tag. Those who have thought a little deeper have presented a more cynical point of view and feel Gilead is only helping themselves to maximize their profit. Truvada kidney failure attorneys have vast experience and a long track record of success in winning cases against multinational pharmaceutical letigations and offer a free consultation and no obligation to file a claim.

Critics stress that giving away only 200,000 bottles of the drug per year barely makes a dent in the number of uninsured Americans that need the drug and that it would take starting at 200,000 bottles and adding 200,000 bottles free per year to make a difference. And then, what is stopping the company from continuing this forever until AIDS is wiped out? Why the ten-year limit? An article in the New York Times quoted Dr. Rochelle P. Walensky from Massachusetts General Hospital and one who has studied the Obama HIV initiative extensively, as calling the Trump/Gilead Truvada giveaway program "a noble effort - but it covers less than 20 percent of the people who need it." That would put the actual number of bottles of Truvada that would be needed at around 1 million annually to do any good. Dr. Walensky also is quoted in The Times as saying "Let's call a spade a spade. The real cost of Truvada is about $60 a year. If you wanted to cover everybody, you'd cut the price to everyone."

Gilead may have a more sinister motive behind their apparent charity and the company could be offering Truvada merely as a marketing promotion to ensure that the drug's patent problems are solved. Some accuse Trump and Gilead of conspiring to ensure that Gilead's other anti-HIV drug, Descovy, a proven safer alternative, has a ready market for its customers when the company transitions to the drug. Descovy was recently given fast-track approval by a panel at the Food and Drug Administration under the assumption of providing a continuous stream of free medication once Truvada's patent expired. At some point, everyone will have transitioned to Descovy via the free giveaway program and when they can no longer get the drug for free they will have to pay the exorbitant $20,000 per year price tag. And speaking of Descovy, Gilead Sciences is being accused of keeping this safer Truvada alternative drug off of the market to maximize Truvada's profits. Truvada is known to cause bone density problems that lead to full-blown osteoporosis causing broken bones. While experts think that bone weakness may be reversible for short-term users of Truvada they are uncertain what the consequences may be for those that take Truvada for more than one year. We will see.

More Recent Truvada Bone Lawsuit News:

No-Cost, No-Obligation Truvada Lawsuit Case Review If You or a Loved One Suffered from Truvada Bone or Kidney Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.